Definitive Contract HHSN261201200069C

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pharmaseq, Inc. The contract is for the development of an &quot;Antibody Array for Cancer Detection&quot; under SBIR Topic 236. The contract has a firm fixed price ceiling value of $150,000.00 and a period of performance ending on March 29, 2009. The contract is designated as a Total Small Business Set-Aside.</p>

This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...

This federal contract award for $389,535 was made to Electronic Biosciences, Inc., a small business biotechnology company, by the National Cancer Institute (NCI) under the Small Business Innovation Research (SBIR) program. The contract is for the development of an &quot;IDEAL AT-HOME PROSTATE SPECIFIC ANTIGEN (PSA) TESTING&quot; solution, which aligns with NCI's mission to support innovative technologies for cancer diagnostics and prevention. The contract is a Firm Fixed Price, Definitive...

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

<p>This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to Singulex, Inc., a small business. The contract is for a Small Business Innovation Research (SBIR) Program Phase I research project in the biomedical field, with a firm fixed price of $149,760 and a period of performance ending on April 30, 2010. As an SBIR Phase I award, this contract supports early-stage research and development efforts. The contract was awarded on September 30, 2009.</p>

<p>This federal contract award, with an identifier of HHSN261201000089C, was issued by the National Cancer Institute (NCI), a civilian agency. The contract was awarded to Dana Pharmaceutical Consulting, Inc., a small business, for a one-year, firm fixed-price SBIR Phase I research project focused on &quot;Facilitating the Transfer of Statistical Methodology into Practice.&quot; The contract has a ceiling value of $100,000.00.</p>

The federal contract award HHSN261200700013C, valued at $749,438.00, was issued by the National Cancer Institute (NCI), a civilian agency, to Scientific Software International, Inc. (SSI) under the Small Business Innovation Research (SBIR) Program Phase II. The contract is for the development of an Outcomes Research System called &quot;OTHER FUNCTIONS MEDPRO&quot; and is a Definitive Contract with a Cost Plus Fixed Fee pricing type. The contract has a total small business set-aside designation...

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>

This federal contract award is for a Small Business Innovation Research (SBIR) Phase II project titled &quot;AUTOMATED MULTI-ARRAY PLATFORM FOR CANCER BIOMARKERS&quot;, awarded by the National Cancer Institute (NCI) to Meso Scale Diagnostics LLC, doing business as Meso Scale Discovery. The $998,408 cost-plus-fixed-fee contract was awarded on September 30, 2009 and has a completion date of January 31, 2012. Meso Scale Diagnostics is a small business that specializes in assay development,...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>